Valneva’s chikungunya vaccine reports positive topline data from Phase 3 trial

Vaccine company Valneva has announced positive Phase 3 pivotal results for its single-shot chikungunya vaccine. “We are a step closer to addressing this major, growing and unmet public health threat,” says the company.